Antibiotic resistance in ocular bacterial pathogens

Indian Journal of Medical Microbiology

Volumn 29, Issue 3, 2011, Pages 218-222

  Sharma, S ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

Antibiotic resistance; bacteria; fluoroquinolones; ocular infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BESIFLOXACIN; CEFALOTIN; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; NEOMYCIN; NORFLOXACIN; OFLOXACIN; POLYMYXIN B; QUINOLONE DERIVATIVE; TETRACYCLINE; TOBRAMYCIN;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL EYE INFECTION; BACTERIUM ISOLATE; BLEPHARITIS; BLOOD EYE BARRIER; BONE MARROW DEPRESSION; CANALICULITIS; CAUSAL ATTRIBUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONJUNCTIVA EPITHELIUM; CONJUNCTIVITIS; CORYNEBACTERIUM; CORYNEBACTERIUM DIPHTHERIAE; CORYNEBACTERIUM MACGINLEYI; DACRYOCYSTITIS; DISEASE ASSOCIATION; DISK DIFFUSION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CHOICE; DRUG PENETRATION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HAEMOPHILUS INFLUENZAE; HUMAN; KERATITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM; NECROTIZING FASCITIS; NOCARDIA; NONHUMAN; ORBIT CELLULITIS; PROTEUS; PSEUDOMONAS INFECTION; REVIEW; SALMONELLA TYPHI; SCLERITIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC THERAPY; TRACHOMA; TREATMENT DURATION; TYPHOID FEVER; UVEITIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 80052630436     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.83903     Document Type: Review

References (34)

1. Fintelmann RE, Hoskins EN, Leitman TM, Keenan JD, Gaynor BD, Cevallos V, et al. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Arch Ophthalmol 2011;129:399-402.
2. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999;37:351-60.
3. Varaldo PE. Antimicrobial resistance and susceptibility testing: An evergreen topic. J Antimicrob Chemother 2002;50:1-4. (Pubitemid 34785247)
4. Kaliamurthy J, Nelson JC, Geraldine P, Parmar P, Kalavathy CM, Thomas PA. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res 2005;37:117-22. (Pubitemid 41022568)
5. Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol 2006;141:282-6.
6. Block SL, Hedrick J, Tyler R, Smith A, Findlay R, Keegan E, et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998). Antimicrob Agents Chemother 2000;44:1650-4. (Pubitemid 30340809)
7. Chalita MR, Hofling-Lima AL, Paranhos A Jr, Schor P, Belfort R Jr. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004;137:43-51. (Pubitemid 38045186)
8. Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008;115:51-6. (Pubitemid 350309422)
9. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8.
10. Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone, gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004;49:109-14. (Pubitemid 38967345)
11. Harper T, Miller D, Flynn HW Jr. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Ophthalmology 2007;114:871-5. (Pubitemid 46635853)
12. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anerobic bacteria. Antimicrob Agents Chemother 2009;53:3552-60.
13. McDonald MB, Blondeau JM, Decory HH, Usner DW, Brunner LS, Haas W, et al. "Multidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitis. New Orleans, USA: Poster presented at Annual meeting of American Academy of Ophthalmology; 2007.
14. Mayo MS, Cook WL, Schlitzer RL, Ward MA, Wilson LA, Ahearn DG. Antibiograms, serotypes, and plasmid profiles of Pseudomonas aeruginosa associated with corneal ulcer and contact lens wear. J Clin Microbiol 1986;24:372-6. (Pubitemid 16046395)
15. Chaudhry NA, Flynn HW Jr, Murray TG, Tabarideh H, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128:509-10. (Pubitemid 29479329)
16. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-502.
17. Pathengay A, Mathai A, Shah GY, Ambatipudi S. Intravitreal piperacillin/tazobactum in the management of multidrug resistant Pseudomonas aeruginosa endophthalmitis. J Cataract Refract Surg 2010;36:2210-1.
18. Chew FL, Soong TK, Shin HC, Samsudin A, Visvaraja S. Topical piperacillin/Tazobactum for recalcitrant Pseudomonas aeruginosa keratitis. J Ocular Pharmacol Therap 2010;26:219-21.
19. Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone, gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004;49:109-14. (Pubitemid 38967345)
20. Leng T, Flynn HW, Miller D, Murray TG, Smiddy WE. Endophthalmitis caused by Proteus species: Antibiotic sensitivities and visual acuity outcomes. Retina 2009;29:1019-24.
21. Sharma S, Desai RU, Pass AB, Saffra NA. Vancomycin-resistant enterococcal endophthalmitis. Arch Ophthalmol 2010;128:794-5.
22. Rishi E, Rishi P, Nandi K, Shroff D, Therese KL. Endophthalmitis caused by Enterococcus faecalis. A case series. Retina 2009;29:214-7.
23. Rau G, Seedor JA, Shah MK, Ritterband DC, Koplin RS. Incidence and clinical characteristics of Enterococcus keratitis. Cornea 2008;27:895-9.
24. Jones DB. Emerging vancomycin reistance: What are we waiting for? Arch Ophthalmol 2010;128:789-91.
25. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including intermediate and heterogenous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139.
26. Sharma V, Sharma S, Garg P, Rao GN. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. Indian J Ophthalmol 2004;52:287-92. (Pubitemid 40116026)
27. Sharma S, Kunimoto DY, Garg P, Rao GN. Trends in antibiotic resistance of corneal pathogens: Part I. An analysis of commonly used ocular antibiotics. Indian J Ophthalmol 1999;47:95-100.
28. Khosravi AD, Mehdinejad M, Heidari M. Bacteriological findings in patients with ocular infection and antibiotic susceptibility patterns of isolated pathogens. Singapore Med J 2007;48:741-3. (Pubitemid 351235328)
29. Sridhar MS, Sharma S, Garg P, Rao GN. Treatment and outcome of Nocardia keratitis. Cornea 2001;20:458-62. (Pubitemid 32565780)
30. Reddy AK, Garg P, Hari Babu K, Gopinathan U, Sharma S. In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis. Curr Eye Res 2010;35:34-8.
31. Funke G, Pagano Neiderer M, Bernauer W. Corynebacterium macginleyi has to date been isolated exclusively from conjunctival swabs. J Clin Microbiol 1998;36:3670-3. (Pubitemid 28533249)
32. Joussen Am, Funke G, Joussen F, Herbertz G. Corynebacterium macginleyi: A conjunctiva specific pathogen. Br J Ophthalmol 2000;84:1420-2.
33. Eguchi H, Kuwahara T, Miyamoto T, Nakayama-Imaohji H, Ichimura M, Hayashi T, et al. High -level fluoroquinolone resistance in ophthalmic clinical isolates belonging to the species Corynebacterium macginleyi. J Clin Microbiol 2008;46:527-32. (Pubitemid 351231297)
34. Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distribution for trachoma. Clin Infect Dis 2010;51:571-4.